NCT07055724View on ClinicalTrials.gov

Study of Eque-cel CAR-T Therapy in Newly Diagnosed Severe AL Amyloidosis

PHASE2Not yet recruitingINTERVENTIONAL
Enrollment

17

Participants

Timeline

Start Date

July 31, 2025

Primary Completion Date

June 30, 2027

Study Completion Date

June 30, 2027

Conditions
AL Amyloidosis
Interventions
BIOLOGICAL

Eque-cel CAR-T Therapy

Participants in this arm receive a single infusion of Eque-cel at a dose of 1.0 x 10\^6 CAR-T cells/kg following lymphodepletion preconditioning with fludarabine and cyclophosphamide. Eque-cel is a fully human BCMA-targeted CAR-T cell therapy designed to recognize and eliminate BCMA-expressing cells.

All Listed Sponsors
lead

Nanjing IASO Biotechnology Co., Ltd.

INDUSTRY